ReviewNature reviews. Cardiology2022
The ongoing quest for the first total artificial heart as destination therapy.
Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Hematologic complications and design challenges in cardiovascular devices.Communications engineering · 2026Review
- Telling is Caring: Prioritizing the Best Interests of Dying Children.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2026Article
- Clinical translation and engineering challenges of soft robotic cardiac sleeves for heart failure.Nature communications · 2026Review
- Beyond Continuous-Flow: The Next Wave of Fully Implantable LVADs and Total Artificial Hearts.Current heart failure reports · 2026Review
- Soft robotic devices for cardiovascular medicine.Nature reviews. Cardiology · 2026Review
- Large Animal Models for Preclinical Evaluation of Heart Valve Prostheses, Left Ventricular Assist Devices and Total Artificial Hearts: A Narrative Review.Biomimetics (Basel, Switzerland) · 2026Review
- 4D flow MRI enhances prototype testing of a total artificial heart.Scientific reports · 2025Article
- Design of a Soft Robotic Artificial Cardiac Wall.Artificial organs · 2025Article
- Toward developing a compact total artificial heart using a soft robotic fluidic transmission system.Science advances · 2025Article
- Materials Advances in Devices for Heart Disease Interventions.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Advances in Mechanical Circulatory Support (MCS): Literature Review.Biomedicines · 2025Review
- Blastocyst complementation: current progress and future directions in xenogeneic organogenesis.Stem cell research & therapy · 2025Review
- A soft robotic total artificial hybrid heart.Nature communications · 2025Article
- Anatomical compatibility of a novel total artificial heart: An in-silico study.Artificial organs · 2025Article
- Mapping the research landscape of artificial hearts: identifying hotspots and frontiers through bibliometric analysis.Frontiers in cardiovascular medicine · 2025Review
- Another, A Few Good Device for End Stage Heart Failure.International journal of heart failure · 2024Article
- Sepsis Management in the Cardiac Intensive Care Unit.Journal of cardiovascular development and disease · 2023Review
- Kidney health and function with left ventricular assist devices.Current opinion in nephrology and hypertension · 2023Review
- Stiffened fibre-like microenvironment based on patterned equidistant micropillars directs chondrocyte hypertrophy.Materials today. Bio · 2023Article
- Stem Cell Therapy, Artificial Heart or Xenotransplantation: What will be New "Regenerative" Strategies in Heart Failure during the Next Decade?Stem cell reviews and reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with end-stage heart disease die because of the scarcity of donor hearts. A total artificial heart (TAH), an implantable machine that replaces the heart, has so far been successfully used in over 1,700 patients as a temporary life-saving technology for bridging to heart transplantation. However, after more than six decades of research on TAHs, a TAH that is suitable for destination therapy is not yet available. High complication rates, bulky devices, poor durability, poor biocompatibility and low patient quality of life are some of the major drawbacks of current TAH devices that must be addressed before TAHs can be used as a destination therapy. Quickly emerging innovations in battery technology, wireless energy transmission, biocompatible materials and soft robotics are providing a promising opportunity for TAH development and might help to solve the drawbacks of current TAHs. In this Review, we describe the milestones in the history of TAH research and reflect on lessons learned during TAH development. We summarize the differences in the working mechanisms of these devices, discuss the next generation of TAHs and highlight emerging technologies that will promote TAH development in the coming decade. Finally, we present current challenges and future perspectives for the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.